Search clinical trials for: multiple myeloma

Total 13013 results

University Health Network, Toronto
Myeloma Canada; The Leukemia and Lymphoma Society of Canada

Not yet recruiting

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Lymphoma, B-Cell | Multiple Myeloma | B Cell Lymphoma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression | Multiple Myeloma Stage III | Aggressive Lymphoma
Brigham and Women's Hospital
Medical University of South Carolina; M.D. Anderson Cancer Center; Massachusetts... and other collaborators

Recruiting

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Multiple Myeloma | Acute Kidney Injury | Light Chain Nephropathy

United States
Washington University School of Medicine
Pfizer; National Comprehensive Cancer Network; Rapid Novor

Not yet recruiting

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry

Multiple Myeloma

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Multiple Myeloma

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Puesta Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma (RRMM)

China
University Medical Center Groningen

Not yet recruiting

Bleeding in Multiple Myeloma (BiMM)

Multiple Myeloma
Pfizer

Not yet recruiting

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Relapsed and Refractory Multiple Myeloma (RRMM)
Universitaire Ziekenhuizen KU Leuven
Janssen Pharmaceutica

Not yet recruiting

Study on the Clinical Efficacy of Teclistamab (TECTONIC)

Hematologic Diseases | Multiple Myeloma

Belgium
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Not yet recruiting

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Centre Hospitalier Universitaire de Saint Etienne

Not yet recruiting

Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma (ProApix)

Multiple Myeloma | Total Knee Replacement

France
Janssen-Cilag Ltd.

Recruiting

A Real-world Study in Participants With Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

France
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital of Wenzhou Medical University; The Affiliated Hospital... and other collaborators

Recruiting

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Multiple Myeloma | Minimal Residual Disease

China
Nanjing IASO Biotechnology Co., Ltd.

Recruiting

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) (FUMANBA-03)

Multiple Myeloma

China
National Cancer Institute (NCI)

Not yet recruiting

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Hard-to-Treat Multiple Myeloma

Multiple Myeloma
Stanford University
Janssen, LP

Not yet recruiting

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Multiple Myeloma | Post Stem Cell Transplant

United States
Assiut University

Not yet recruiting

Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

Multiple Myeloma
Durham VA Medical Center
Duke University

Not yet recruiting

Telehealth-based Symptom Management for Veterans Treated With Selinexor (Selinexor)

Multiple Myeloma | Large-cell Lymphoma
Changchun GeneScience Pharmaceutical Co., Ltd.

Not yet recruiting

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Breast Cancer Subjects

China
Opna Bio LLC

Recruiting

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Multiple Myeloma or Plasmacytoma

China, Russian Federation
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple Myeloma | Plasmacytoma

China, Russian Federation
Janssen Research & Development, LLC

Recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, United States, Australia
Ontario Clinical Oncology Group (OCOG)
Pfizer

Not yet recruiting

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma

Canada
Nantes University Hospital

Not yet recruiting

Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study (DELICATESSE)

Myeloma Multiple
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
University Hospital, Angers

Not yet recruiting

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. (ALHERT)

Lymphoma | Leukemia | Multiple Myeloma

France
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Peking University First Hospital

Recruiting

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Multiple Myeloma

China
IRCCS Policlinico S. Matteo

Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) (ProDigALIty)

AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

Italy
Cullinan Therapeutics Inc.

Not yet recruiting

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
Changzhou No.2 People's Hospital

Not yet recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Multiple Myeloma

China
Dickran Kazandjian, MD
Regeneron Pharmaceuticals

Not yet recruiting

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT)

Multiple Myeloma

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China
Tufts Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Jack Khouri

Not yet recruiting

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Multiple Myeloma | Refractory Multiple Myeloma | Cytokine Release Syndrome | Immune Effector Cell Associated Neurotoxicity Syndrome

United States
Adriana Rossi

Not yet recruiting

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Early Assessment of Cardiac Function After Treatment With CAR-T Cells (Cardio CAR-T)

Lymphoma, B-Cell | Multiple Myeloma | Acute Lymphoblastic Leukemia | Hematologic Malignancy | Car T- Cell

France
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital

Recruiting

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Multiple Myeloma | Rectal Cancer | Cholangiocarcinoma | Colon Cancer

United States
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)

Not yet recruiting

Precision Medicine Study

Multiple Myeloma

United States

Search clinical trials for: multiple myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations